

a precision value & health team





#### David Ziedman

SVP global accounts + 31 6 14 602 444 david.ziedman@a-cross.com



### Omnichannel for Payers: A big opportunity for pharma

November 16<sup>th</sup>, 2022

### Ground rules

- This webinar will take max 60 minutes, followed by questions
- You can submit **questions** at any time via the "Questions" box

- Questions	5
	^
[Enter a question for staff]	*
	-

- Please give us your feedback!
  - Right after the webinar a short satisfaction survey will be launched. We would love to know your opinion!
- The webinar will be **recorded** and made available after the session. We will send you an email with the details





2

Why are you here?

#### Quick poll question:

# How comfortable are you with the concept of an omnichannel approach for payers?











Want to know the best way to engage with your Payer audiences?

Let them tell you!







What percentage of US payers prefer an omnichannel approach?

- 28%
- 48%
- 68%
- 88%







#### The questions we will address in this webinar...

- 1. What are the trends impacting on Payers?
- 2. What are the Omnichannel opportunities for Pharma to better serve and impact Payers?
- 3. Which online (digital) and offline (traditional F2F) channels will support improvement of overall reach and impact within your Omnichannel plan?
- 4. Which services and resources do Payers want and in which way do they want it?
- 5. When and how do Payers want support for upcoming launches?
- 6. Where can you improve compared to your competitors on overall Cx as well as at channel level?








# 1. What are the trends impacting on Payers?





Omnichannel for payers needs to take into account all these trends to ensure success










Current challenges facing the industry







#### The impact of COVID-19







#### The impact of COVID-19








#### The impact of COVID-19







Current challenges facing the industry










#### The challenge of multiple payer stakeholders







Current challenges facing the industry







Medical knowledge is expanding faster than our ability to assimilate and apply it effectively

The doubling time of medical knowledge in 1960 was 50 years; in 1980: 7 years; and in 2010: 3.5 years

In 2020, it was projected to be just 73 days<sup>1</sup>

1. Denson et al. Trans Am Clin Climatol Assoc. 2011; 122: 48-58





Current challenges facing the industry

### DIGITAL VS TRADITIONAL











# 2. What are the Omnichannel opportunities for Pharma to better serve and impact Payers?







We recently ran Navigator365 Payer research in the US to gain insights on channel reach/impact, content/services, 3<sup>rd</sup> party usage and benchmarking

MARKET – PAYER UNITED STATES N=167

The survey sample comprised 167 Payers in United States

For relevance, the questionnaire used in this survey included screening questions. Not all respondents were exposed to all questions. Average length of interview: 40-45 minutes. The research was carried out in Q4 2022 The Navigator365 Payer research is also being run across the globe as we speak

Note: We include those relevant subnational (regional/local) payers per country that are relevant for Omnichannel

Source: (≡) Navigator365<sup>™</sup> Payer

17/11/2022 © Across Health





#### Today we will cover some highlights from the four Parts of the Navigator365 Payer insights








17/11/2022 © Across Health

Proprietary and confidential information



#### A representative sample of 167 US payers across employers and roles

**EMPLOYER** – PAYER UNITED STATES N=167








17/11/2022 © Across Health

Proprietary and confidential information



#### Digital channels are important to Payers: 62% rate them as (very) important



#### **IMPORTANCE OF PHARMA DIGITAL CHANNELS** – PAYER UNITED STATES N=167


Importance of pharma digital channels to respondents on a 0-10 scale Score grouping: Very important = 9-10; important = 7-8; neutral = 5-6; slightly unimportant = 3-4; very unimportant = 0-2







While 70% of Payers want Digital-only or a mix of Digital + F2F, the reach of the top digital channels is only 43% creating a large opportunity to close the Digital Divide



The Digital Divide is defined as the delta between the % of respondents preferring digital or mix and the average % reach of the top 3 online promo and medical channels ('epharma reach')




17/11/2022 © Across Health

Reimagine customer engagement Webinars ACROSS HEALTH 25


Proprietary and confidential information

#### In contrast, 49% of 2,060 US specialists want Digital-only or a mix of Digital + F2F

The reach of the top digital channels is 33%. Meaning there is a greater demand and gap for promotional engagement with payers vs specialists.



#### And only 26% of Payers say that most Pharma companies are delivering relevant content





N=167



17/11/2022 © Across Health

Proprietary and confidential information



## 3.

Which online (digital) and offline (traditional F2F) channels will support improvement of overall reach and impact within your Omnichannel plan?



## We cover the reach, impact and frequency of over 50 channels across Promo, Medical, Paid and Earned










Proprietary and confidential informatior

#### To compare impact- of channels, we apply the MultiChannel eQuivalent (MCQ) approach



\* For educational channels: ...of 1 MSL face-to-face visit





17/11/2022 © Across Health

Proprietary and confidential information

### We can see some medical channels having high impact, while other promo and medical channels offer higher reach with still decent impact



engagement Webinars

Proprietary and confidential informatic

31


Do channels have a greater impact with US specialists or payers?

- Greater with specialists
- Greater with payers
- The same, depends on the channel

















## 4. Which services and resources do Payers want and in which way do they want it?





# Self-service portals supported by content and services rated as highest importance when it comes to digital channels



**DESIRED DIGITAL SERVICES FROM PHARMA** – PAYER UNITED STATES

N=167

Reimagine customer engagement

Respondents were asked to distribute 100 points to no more than 3 options Score = sum of points averaged among respondents

□ Webinars



7/11/2022 © Across Health



What is the most valuable resource from pharma for payers?

- Clinical trial information
- Pricing and contracting information
- Clinical guidelines
- Comparative product information





17/11/2022 © Across Health Proprietary and confidential information




### Overall from pharma, clinical trial info even more important vs. pricing/contracting

#### MOST VALUABLE RESOURCES FROM PHARMA - PAYER UNITED STATES

N=167

Reimagine customer engagement



Respondents were asked to distribute 100 points to no more than 3 options Score = sum of points averaged among respondents


□ Webinars



7/11/2022 © Across Health



### Visuals and charts are the leading formats followed closely by textual summaries



#### **PREFERRED DIGITAL FORMAT** – PAYER UNITED STATES

N=167

Reimagine customer engagement

Respondents were asked to distribute 100 points to no more than 3 options Score = sum of points averaged among respondents


□ Webinars



7/11/2022 © Across Health



## When it comes to the market access AM specifically, pricing and clinical/economic information is the most desired



**MOST VALUABLE CONTRIBUTION OF AM** – PAYER UNITED STATES

N=167

Respondents were asked to distribute 100 points to no more than 3 options Score = sum of points averaged among respondents





17/11/2022 © Across Health




# 5.

# When and how do Payers want support for upcoming launches?





### Payers want info before and around the time of product launch



#### $\label{eq:preferred period for payer-related info from pharma - {\sf PAYER UNITED STATES}$

N=167

% among respondents






17/11/2022 © Across Health




## When it comes to the market access AM and launch, a mix of F2F remote and email is desired

### ACCOUNT MANAGER FORMAT IN LAUNCH SETTING - PAYER UNITED STATES N=167



% among respondents









# 6.

# Where can you improve compared to your competitors on overall Cx as well as at channel level?







## When it comes to overall Cx at company level, as measured by the Customer Effort Score (CES), Pfizer and GSK are in the lead

### Neither agree nor disagree Strongly disagree Disagree Somewhat disagree Somewhat agree Agree Strongly agree N=167 CES = 5.4Pfizer 26% GlaxoSmithKline 25% 29% 30% CES = 5.220% 30% 40% 50% 60% 80% 90%

**CUSTOMER EFFORT SCORE** – PAYER UNITED STATES

Respondents were asked to rate between 1 = strongly disagree to 7 = strongly agree % = # of respondents who selected option out of total number of respondents

CES = average selected score






17/11/2022 © Across Health roprietary and confidential information



## In contrast, when it comes to market access AMs (as an example channel), AbbVie and Pfizer are in the lead





17/11/2022 © Across Health



# How can we help?















## BACKGROUND


- A global biopharma company wanted to develop an omnichannel approach for payers in EU5/Canada.
- The main challenge was that different countries had different payer types.

## T APPROACH

- Across Health developed omnichannel blueprints for payers at regional/local levels integrating the MAM\* into the journey.
- The 6-step approach to developing an omnichannel strategy was used.
- In each country, the Payer Navigator 2.0 was used to generate key insights for channel and content affinities.
- Across Health conducted strategic workshops in each country; key outputs were used to prioritize recommendations.













### **© RESULTS**

- Different types of payers in different countries were identified.
- Accordingly, for each country, recommendations on MVPs\* and further execution plans were provided, based on the outputs from each country workshop.

## 

Maximizing omnichannel payer interactions for market access outcomes can increase business impact, provide added value to and deepen relationships with payers, and differentiate the company from the competition.

\*MVP : Minimum Viable Product





### Conclusions



- The payer market has changed digital transformation was rapidly accelerated and we need to think differently about engagement
- Payers prefer an omnichannel approach to engagement
- Payer digital engagement from life sciences is not yet meeting the needs of Payers there is an opportunity to lead this space
- There is a bigger opportunity to reach US payers through omnichannel than US Specialists





### Want to understand more about payers in your market?





17/11/2022 © Across Health Proprietary and confidential information

### Please give us your feedback!

Right after the webinar a short satisfaction survey will be launched. We would love to know your opinion!






17/11/2022 © Across Health Proprietary and confidential information



### Want to know more? Check out our recorded webinars... and much more



#### Resources & insights



### across.health/resources



17/11/2022 © Across Health



https://www.across.health